GIVLAARI

NDC 71336-1001 · Alnylam Pharmaceuticals, Inc.

Generic namegivosiran sodium

Dosage formINJECTION, SOLUTION

RouteSUBCUTANEOUS

Active ingredient(s)GIVOSIRAN SODIUM

Strength189 mg/mL

Pharmacologic classAminolevulinate Synthase 1-directed RNA Interaction [EPC], Decreased RNA Integrity [PE], RNA, Small Interfering [CS], Small Interfering RNA [EPC]

Marketing categoryNDA

Packages

71336-1001-1 — 1 VIAL, SINGLE-USE in 1 CARTON (71336-1001-1) / 1 mL in 1 VIAL, SINGLE-USE

Billed under HCPCS

J0223 — Injection, givosiran, 0.5 mg Medicare Part B payment limit (ASP + 6%): $120.92

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.

Read from: FDA National Drug Code Directory, product.txt and package.txt (accessdata.fda.gov/cder/ndctext.zip) — Snapshot retrieved 2026-08-24, loaded 2026-08-24; CMS Medicare Part B Drug Average Sales Price (ASP) Pricing Files (cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) -- the NDC-HCPCS crosswalk and Part B payment limit files — 2026 Q3 (July 2026 release). All data sources · How to read the labels